Topical pimecrolimus in the treatment of human allergic contact dermatitis
Contact dermatitis is a common clinical problem, with prevalent sensitizers being cosmetics, metals, medicines, and plants. Plants of the Toxicodendron species cause allergic contact dermatitis (ACD) in 50% to 70% of the population. Pimecrolimus is an ascomycin macrolactam developed for the treatmen...
Gespeichert in:
| Veröffentlicht in: | Annals of allergy, asthma, & immunology asthma, & immunology, 2003-12, Vol.91 (6), p.563-566 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 566 |
|---|---|
| container_issue | 6 |
| container_start_page | 563 |
| container_title | Annals of allergy, asthma, & immunology |
| container_volume | 91 |
| creator | Amrol, David Keitel, Duane Hagaman, David Murray, John |
| description | Contact dermatitis is a common clinical problem, with prevalent sensitizers being cosmetics, metals, medicines, and plants. Plants of the
Toxicodendron species cause allergic contact dermatitis (ACD) in 50% to 70% of the population. Pimecrolimus is an ascomycin macrolactam developed for the treatment of inflammatory skin diseases and approved by the US Food and Drug Administration for atopic dermatitis. There are studies supporting the effectiveness of macrolactams when administered before antigen challenge, but there are no studies describing the effectiveness of these drugs in the treatment of established human ACD.
To investigate the effect of topical pimecrolimus in the treatment of
Toxicodendron-induced ACD once rash is evident.
Poison ivy tincture was applied to the bilateral anterior forearms of 12 subjects with Finn Chambers (Allerderm Diagnostic Products, Petaluma, CA). After dermatitis was evident, volunteers treated each arm twice daily with either 1% topical pimecrolimus cream or placebo in a blinded fashion. Outcomes measured were a dermatitis grading score and time to rash and itch resolution.
The median ± SEM time for rash resolution was 16.55 ± 1.59 days in the treatment group and 16.27 ± 1.82 days in the placebo group (
P = 0.601). The median time for itch resolution was 4.73 ± 1.56 days in the treatment group and 4.91 ± 1.59 days in the placebo group (
P = 0.167). The average dermatitis score was 2.26 ± 0.17 in the treatment group and 2.32 ± 0.15 in the placebo group (
P = 0.62).
The application of topical pimecrolimus is ineffective in the treatment of ongoing
Toxicodendroninduced ACD. |
| doi_str_mv | 10.1016/S1081-1206(10)61535-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17705299</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1081120610615359</els_id><sourcerecordid>523671811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-c849e05b40e009511f2ed60c2feabfcaa2fb3001ecedbb888c1a8200ed52e823</originalsourceid><addsrcrecordid>eNqFkE1r3DAQhkVoSLab_oQWUWhoDk5HsmTLpxJCmw8COWTvQpbHjRZ_bCQ5kH8fObtlIZecNIhnXt55CPnK4JwBK349MFAsYxyKnwzOCiZzmVUHZJEGkQmRF5_S_B85Jp9DWAMAU0V-RI6ZKAGEYAtyuxo3zpqOblyP1o-d66dA3UDjI9Lo0cQeh0jHlj5OvRmo6Tr0_5yldhyisZE26HsTXXThhBy2pgv4Zfcuyervn9XldXZ3f3VzeXGXWSGqmFklKgRZC0CASjLWcmwKsLxFU7fWGN7WeWqKFpu6VkpZZhQHwEZyVDxfktNt7MaPTxOGqHsXLHadGXCcgmZlCZJXVQK_vwPX4-SHVE1z4KWqoJQJklso3R6Cx1ZvvOuNf9EM9Cxav4nWs8X56020nsO_7cKnusdmv7Uzm4AfO8CE5Lf1ZrAu7DmZF3nO56DfWw6TsmeHXgfrcEjHO4826mZ0H1R5BdfpmjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>202789075</pqid></control><display><type>article</type><title>Topical pimecrolimus in the treatment of human allergic contact dermatitis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Amrol, David ; Keitel, Duane ; Hagaman, David ; Murray, John</creator><creatorcontrib>Amrol, David ; Keitel, Duane ; Hagaman, David ; Murray, John</creatorcontrib><description>Contact dermatitis is a common clinical problem, with prevalent sensitizers being cosmetics, metals, medicines, and plants. Plants of the
Toxicodendron species cause allergic contact dermatitis (ACD) in 50% to 70% of the population. Pimecrolimus is an ascomycin macrolactam developed for the treatment of inflammatory skin diseases and approved by the US Food and Drug Administration for atopic dermatitis. There are studies supporting the effectiveness of macrolactams when administered before antigen challenge, but there are no studies describing the effectiveness of these drugs in the treatment of established human ACD.
To investigate the effect of topical pimecrolimus in the treatment of
Toxicodendron-induced ACD once rash is evident.
Poison ivy tincture was applied to the bilateral anterior forearms of 12 subjects with Finn Chambers (Allerderm Diagnostic Products, Petaluma, CA). After dermatitis was evident, volunteers treated each arm twice daily with either 1% topical pimecrolimus cream or placebo in a blinded fashion. Outcomes measured were a dermatitis grading score and time to rash and itch resolution.
The median ± SEM time for rash resolution was 16.55 ± 1.59 days in the treatment group and 16.27 ± 1.82 days in the placebo group (
P = 0.601). The median time for itch resolution was 4.73 ± 1.56 days in the treatment group and 4.91 ± 1.59 days in the placebo group (
P = 0.167). The average dermatitis score was 2.26 ± 0.17 in the treatment group and 2.32 ± 0.15 in the placebo group (
P = 0.62).
The application of topical pimecrolimus is ineffective in the treatment of ongoing
Toxicodendroninduced ACD.</description><identifier>ISSN: 1081-1206</identifier><identifier>EISSN: 1534-4436</identifier><identifier>DOI: 10.1016/S1081-1206(10)61535-9</identifier><identifier>PMID: 14700441</identifier><identifier>CODEN: ANAEA3</identifier><language>eng</language><publisher>McLean, VA: Elsevier Inc</publisher><subject>Administration, Topical ; Adolescent ; Adult ; Aged ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Biological and medical sciences ; Dermatitis, Allergic Contact - drug therapy ; Dermatitis, Allergic Contact - etiology ; Dermatitis, Toxicodendron - drug therapy ; Dermatitis, Toxicodendron - etiology ; Dermatologic Agents - therapeutic use ; Exanthema - drug therapy ; Exanthema - etiology ; Female ; Histamine and antagonists. Allergy ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pruritus - drug therapy ; Pruritus - etiology ; Severity of Illness Index ; Tacrolimus - analogs & derivatives ; Tacrolimus - therapeutic use ; Time Factors ; Toxicodendron ; Treatment Outcome</subject><ispartof>Annals of allergy, asthma, & immunology, 2003-12, Vol.91 (6), p.563-566</ispartof><rights>2003 American College of Allergy, Asthma & Immunology</rights><rights>2004 INIST-CNRS</rights><rights>Copyright American College of Allergy and Immunology Dec 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-c849e05b40e009511f2ed60c2feabfcaa2fb3001ecedbb888c1a8200ed52e823</citedby><cites>FETCH-LOGICAL-c449t-c849e05b40e009511f2ed60c2feabfcaa2fb3001ecedbb888c1a8200ed52e823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S1081-1206(10)61535-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15363329$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14700441$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Amrol, David</creatorcontrib><creatorcontrib>Keitel, Duane</creatorcontrib><creatorcontrib>Hagaman, David</creatorcontrib><creatorcontrib>Murray, John</creatorcontrib><title>Topical pimecrolimus in the treatment of human allergic contact dermatitis</title><title>Annals of allergy, asthma, & immunology</title><addtitle>Ann Allergy Asthma Immunol</addtitle><description>Contact dermatitis is a common clinical problem, with prevalent sensitizers being cosmetics, metals, medicines, and plants. Plants of the
Toxicodendron species cause allergic contact dermatitis (ACD) in 50% to 70% of the population. Pimecrolimus is an ascomycin macrolactam developed for the treatment of inflammatory skin diseases and approved by the US Food and Drug Administration for atopic dermatitis. There are studies supporting the effectiveness of macrolactams when administered before antigen challenge, but there are no studies describing the effectiveness of these drugs in the treatment of established human ACD.
To investigate the effect of topical pimecrolimus in the treatment of
Toxicodendron-induced ACD once rash is evident.
Poison ivy tincture was applied to the bilateral anterior forearms of 12 subjects with Finn Chambers (Allerderm Diagnostic Products, Petaluma, CA). After dermatitis was evident, volunteers treated each arm twice daily with either 1% topical pimecrolimus cream or placebo in a blinded fashion. Outcomes measured were a dermatitis grading score and time to rash and itch resolution.
The median ± SEM time for rash resolution was 16.55 ± 1.59 days in the treatment group and 16.27 ± 1.82 days in the placebo group (
P = 0.601). The median time for itch resolution was 4.73 ± 1.56 days in the treatment group and 4.91 ± 1.59 days in the placebo group (
P = 0.167). The average dermatitis score was 2.26 ± 0.17 in the treatment group and 2.32 ± 0.15 in the placebo group (
P = 0.62).
The application of topical pimecrolimus is ineffective in the treatment of ongoing
Toxicodendroninduced ACD.</description><subject>Administration, Topical</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Dermatitis, Allergic Contact - drug therapy</subject><subject>Dermatitis, Allergic Contact - etiology</subject><subject>Dermatitis, Toxicodendron - drug therapy</subject><subject>Dermatitis, Toxicodendron - etiology</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Exanthema - drug therapy</subject><subject>Exanthema - etiology</subject><subject>Female</subject><subject>Histamine and antagonists. Allergy</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pruritus - drug therapy</subject><subject>Pruritus - etiology</subject><subject>Severity of Illness Index</subject><subject>Tacrolimus - analogs & derivatives</subject><subject>Tacrolimus - therapeutic use</subject><subject>Time Factors</subject><subject>Toxicodendron</subject><subject>Treatment Outcome</subject><issn>1081-1206</issn><issn>1534-4436</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1r3DAQhkVoSLab_oQWUWhoDk5HsmTLpxJCmw8COWTvQpbHjRZ_bCQ5kH8fObtlIZecNIhnXt55CPnK4JwBK349MFAsYxyKnwzOCiZzmVUHZJEGkQmRF5_S_B85Jp9DWAMAU0V-RI6ZKAGEYAtyuxo3zpqOblyP1o-d66dA3UDjI9Lo0cQeh0jHlj5OvRmo6Tr0_5yldhyisZE26HsTXXThhBy2pgv4Zfcuyervn9XldXZ3f3VzeXGXWSGqmFklKgRZC0CASjLWcmwKsLxFU7fWGN7WeWqKFpu6VkpZZhQHwEZyVDxfktNt7MaPTxOGqHsXLHadGXCcgmZlCZJXVQK_vwPX4-SHVE1z4KWqoJQJklso3R6Cx1ZvvOuNf9EM9Cxav4nWs8X56020nsO_7cKnusdmv7Uzm4AfO8CE5Lf1ZrAu7DmZF3nO56DfWw6TsmeHXgfrcEjHO4826mZ0H1R5BdfpmjQ</recordid><startdate>20031201</startdate><enddate>20031201</enddate><creator>Amrol, David</creator><creator>Keitel, Duane</creator><creator>Hagaman, David</creator><creator>Murray, John</creator><general>Elsevier Inc</general><general>American College of Allergy, Asthma, & Immunology</general><general>American College of Allergy and Immunology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20031201</creationdate><title>Topical pimecrolimus in the treatment of human allergic contact dermatitis</title><author>Amrol, David ; Keitel, Duane ; Hagaman, David ; Murray, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-c849e05b40e009511f2ed60c2feabfcaa2fb3001ecedbb888c1a8200ed52e823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Administration, Topical</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Dermatitis, Allergic Contact - drug therapy</topic><topic>Dermatitis, Allergic Contact - etiology</topic><topic>Dermatitis, Toxicodendron - drug therapy</topic><topic>Dermatitis, Toxicodendron - etiology</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Exanthema - drug therapy</topic><topic>Exanthema - etiology</topic><topic>Female</topic><topic>Histamine and antagonists. Allergy</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pruritus - drug therapy</topic><topic>Pruritus - etiology</topic><topic>Severity of Illness Index</topic><topic>Tacrolimus - analogs & derivatives</topic><topic>Tacrolimus - therapeutic use</topic><topic>Time Factors</topic><topic>Toxicodendron</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Amrol, David</creatorcontrib><creatorcontrib>Keitel, Duane</creatorcontrib><creatorcontrib>Hagaman, David</creatorcontrib><creatorcontrib>Murray, John</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Annals of allergy, asthma, & immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Amrol, David</au><au>Keitel, Duane</au><au>Hagaman, David</au><au>Murray, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Topical pimecrolimus in the treatment of human allergic contact dermatitis</atitle><jtitle>Annals of allergy, asthma, & immunology</jtitle><addtitle>Ann Allergy Asthma Immunol</addtitle><date>2003-12-01</date><risdate>2003</risdate><volume>91</volume><issue>6</issue><spage>563</spage><epage>566</epage><pages>563-566</pages><issn>1081-1206</issn><eissn>1534-4436</eissn><coden>ANAEA3</coden><abstract>Contact dermatitis is a common clinical problem, with prevalent sensitizers being cosmetics, metals, medicines, and plants. Plants of the
Toxicodendron species cause allergic contact dermatitis (ACD) in 50% to 70% of the population. Pimecrolimus is an ascomycin macrolactam developed for the treatment of inflammatory skin diseases and approved by the US Food and Drug Administration for atopic dermatitis. There are studies supporting the effectiveness of macrolactams when administered before antigen challenge, but there are no studies describing the effectiveness of these drugs in the treatment of established human ACD.
To investigate the effect of topical pimecrolimus in the treatment of
Toxicodendron-induced ACD once rash is evident.
Poison ivy tincture was applied to the bilateral anterior forearms of 12 subjects with Finn Chambers (Allerderm Diagnostic Products, Petaluma, CA). After dermatitis was evident, volunteers treated each arm twice daily with either 1% topical pimecrolimus cream or placebo in a blinded fashion. Outcomes measured were a dermatitis grading score and time to rash and itch resolution.
The median ± SEM time for rash resolution was 16.55 ± 1.59 days in the treatment group and 16.27 ± 1.82 days in the placebo group (
P = 0.601). The median time for itch resolution was 4.73 ± 1.56 days in the treatment group and 4.91 ± 1.59 days in the placebo group (
P = 0.167). The average dermatitis score was 2.26 ± 0.17 in the treatment group and 2.32 ± 0.15 in the placebo group (
P = 0.62).
The application of topical pimecrolimus is ineffective in the treatment of ongoing
Toxicodendroninduced ACD.</abstract><cop>McLean, VA</cop><pub>Elsevier Inc</pub><pmid>14700441</pmid><doi>10.1016/S1081-1206(10)61535-9</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1081-1206 |
| ispartof | Annals of allergy, asthma, & immunology, 2003-12, Vol.91 (6), p.563-566 |
| issn | 1081-1206 1534-4436 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17705299 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Administration, Topical Adolescent Adult Aged Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Biological and medical sciences Dermatitis, Allergic Contact - drug therapy Dermatitis, Allergic Contact - etiology Dermatitis, Toxicodendron - drug therapy Dermatitis, Toxicodendron - etiology Dermatologic Agents - therapeutic use Exanthema - drug therapy Exanthema - etiology Female Histamine and antagonists. Allergy Humans Male Medical sciences Middle Aged Pharmacology. Drug treatments Pruritus - drug therapy Pruritus - etiology Severity of Illness Index Tacrolimus - analogs & derivatives Tacrolimus - therapeutic use Time Factors Toxicodendron Treatment Outcome |
| title | Topical pimecrolimus in the treatment of human allergic contact dermatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A48%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Topical%20pimecrolimus%20in%20the%20treatment%20of%20human%20allergic%20contact%20dermatitis&rft.jtitle=Annals%20of%20allergy,%20asthma,%20&%20immunology&rft.au=Amrol,%20David&rft.date=2003-12-01&rft.volume=91&rft.issue=6&rft.spage=563&rft.epage=566&rft.pages=563-566&rft.issn=1081-1206&rft.eissn=1534-4436&rft.coden=ANAEA3&rft_id=info:doi/10.1016/S1081-1206(10)61535-9&rft_dat=%3Cproquest_cross%3E523671811%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=202789075&rft_id=info:pmid/14700441&rft_els_id=S1081120610615359&rfr_iscdi=true |